List Title | APhA DrugInfoLine

Cardiology

SORT BY: Most Recent Most Viewed

December 2, 2019

Survey suggests overuse of aspirin for primary prevention of CVD

READ

PREVIEW
Data from the National Health Interview Survey published in the Annals of Internal Medicine suggest that approximately 29 million Americans are taking daily aspirin for primary prevention...
November 12, 2019

Recent study finds dapagliflozin improves heart failure outcomes regardless of diabetes status

READ

PREVIEW
Use of dapagliflozin (Farxiga—AstraZeneca) in patients with heart failure (HF) and a reduced ejection fraction (EF) decreased the risk of worsening HF or cardiovascular (CV) death regardless of...
October 15, 2019

Stopping statins in older patients may result in increased CV risk

READ

PREVIEW
Stopping statins used by older patients for primary prevention was associated with an increased risk of cardiovascular (CV) adverse events such as coronary, cerebrovascular, and other vascular...
October 8, 2019

DOACs are useful for older patients with atrial fibrillation

READ

PREVIEW
According to a retrospective analysis published in the Journal of the American Geriatrics Society, use of direct oral anticoagulants (DOACs) in older patients with nonvalvular atrial...
August 27, 2019

Aclidinium not shown to increase CV risk in patients with COPD

READ

PREVIEW
Use of aclidinium bromide (Tudorza Pressair—Circassia) in patients with chronic obstructive pulmonary disease (COPD) and established cardiovascular (CV) disease or CV risk factors was noninferior...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.